Noopept
![]() |
|
![]() |
|
Systematic (IUPAC) name | |
---|---|
Ethyl 1-(phenylacetyl)-L-prolylglycinate
|
|
Clinical data | |
Legal status |
|
Identifiers | |
CAS Number | 157115-85-0 ![]() |
PubChem | CID: 180496 |
ChemSpider | 157065 ![]() |
Synonyms | N-Phenylacetyl-L-prolylglycine ethyl ester |
Chemical data | |
Formula | C17H22N2O4 |
Molecular mass | 318.367 g/mol |
|
|
|
|
![]() ![]() |
Noopept (Russian: Ноопепт; GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, US Patent number 5,439,930 issued 8/8/1995.[1] It is sold as a dietary supplement in the US[citation needed] and as a medication in other countries.[which?]
Mechanism of action
Noopept is not a racetam (due to not having a 2-oxo-pyrrolidine skeleton),[2] but is generally grouped together in the same category because it shares similar mechanisms of action with the racetam family, mainly modulation of the acetylcholine system, as well as modulation of AMPA receptors.[3] When compared to traditional racetams, it has been found to be, according to studies, 1000 times more potent than the prototypical racetam drug, piracetam.[4] Noopept is a prodrug for the endogenous peptide cycloprolylglycine.[5]
Pharmacokinetics
Peak plasma noopept concentrations of 13-33 μg/L are reached within one hour after a single 20 mg oral dose. The half-life averages about 1 hour in healthy individuals. It is mainly cleared renally as a series of metabolites produced by amide and ester hydrolysis, deacylation and aromatic hydroxylation. Noopept may be quantitated in biofluids by liquid chromatography with one of several different detection techniques.[6][7]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
- ↑ PatentGenius.com http://www.patentgenius.com/patent/5439930.html
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ S.S. Boiko, S.A. Korotkov, V.P. Zherdev et al. Interspecific differences of noopept pharmacokinetics. Eksp. Klin. Farmakol. 67: 40–43, 2004.
- ↑ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 10th edition, Biomedical Publications, Seal Beach, CA, 2014, p. 1524-1525. http://www.biomedicalpublications.com/noopept.pdf
- Pages with reference errors
- Drugs with non-standard legal status
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing Russian-language text
- Articles with unsourced statements from April 2016
- All articles with specifically marked weasel-worded phrases
- Articles with specifically marked weasel-worded phrases from April 2016
- Racetams
- Nootropics
- Pyrrolidines
- Ethyl esters
- Russian drugs